Revelation Competitors
| REVB Stock | USD 1.40 0.07 4.76% |
Revelation Biosciences vs Fluoropharma Medical Correlation
Very good diversification
The correlation between Revelation Biosciences and FPMI is -0.21 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Revelation Biosciences and FPMI in the same portfolio, assuming nothing else is changed.
Moving against Revelation Stock
| 0.79 | 6C1 | CytomX Therapeutics | PairCorr |
| 0.78 | CMB | Cambium Bio Earnings Call Next Week | PairCorr |
| 0.71 | DNTH | Dianthus Therapeutics | PairCorr |
| 0.7 | PYC | Physiomics Plc | PairCorr |
| 0.68 | DRTS | Alpha Tau Medical | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Revelation Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Revelation Biosciences Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Revelation Biosciences and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Revelation and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Revelation Biosciences does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Revelation Stock performing well and Revelation Biosciences Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Revelation Biosciences' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| KLDO | 146.28 | 73.72 | 0.00 | (4.50) | 0.00 | 0.00 | 4,998 | |||
| IVBT | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| XENO | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| CALA | 21.70 | 5.87 | 0.08 | (1.50) | 20.34 | 100.00 | 280.00 | |||
| NMRD | 1.49 | (0.80) | 0.00 | (1.46) | 0.00 | 0.00 | 50.00 | |||
| SYVC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| SNNAQ | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| FPMI | 2.98 | 1.42 | 0.00 | 1.07 | 0.00 | 0.00 | 100.00 |
Cross Equities Net Income Analysis
Compare Revelation Biosciences and related stocks such as Kaleido Biosciences, Innovation1 Biotech, and Xeno Transplants Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| XENO | (46.7 K) | (256.4 K) | (256.4 K) | (256.4 K) | (256.4 K) | (256.4 K) | (256.4 K) | (256.4 K) | (256.4 K) | (256.4 K) | (256.4 K) | (256.4 K) | (256.4 K) | (256.4 K) | (256.4 K) | (230.7 K) | (242.3 K) |
| SYVC | (2.9 M) | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (3.6 M) | (3.8 M) |
Revelation Biosciences and related stocks such as Kaleido Biosciences, Innovation1 Biotech, and Xeno Transplants Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Revelation Biosciences financial statement analysis. It represents the amount of money remaining after all of Revelation Biosciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Revelation Biosciences Competitive Analysis
The better you understand Revelation Biosciences competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Revelation Biosciences' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Revelation Biosciences' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Revelation Biosciences Competition Performance Charts
Five steps to successful analysis of Revelation Biosciences Competition
Revelation Biosciences' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Revelation Biosciences in relation to its competition. Revelation Biosciences' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Revelation Biosciences in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Revelation Biosciences' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Revelation Biosciences, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Revelation Biosciences position
In addition to having Revelation Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Drugs Thematic Idea Now
Drugs
Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery. The Drugs theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Drugs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Revelation Biosciences Correlation with its peers. For information on how to trade Revelation Stock refer to our How to Trade Revelation Stock guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revelation Biosciences. Anticipated expansion of Revelation directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Revelation Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Revelation Biosciences requires distinguishing between market price and book value, where the latter reflects Revelation's accounting equity. The concept of intrinsic value - what Revelation Biosciences' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Revelation Biosciences' price substantially above or below its fundamental value.
It's important to distinguish between Revelation Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Revelation Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Revelation Biosciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.